Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours

Next Previous
Trial Profile

A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OMO-2 (Primary)
  • Indications Lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors DeuterOncology

Most Recent Events

  • 09 Sep 2025 According to DeuterOncology media release, the company announced that based on safety, pharmacokinetic and efficacy results the company has initiated an expansion cohort in selected first-line MET exon 14 skip NSCLC patients to further validate the safety and efficacy of the 60mg once-daily regimen.
  • 09 Sep 2025 According to DeuterOncology media release, the company announced that compelling safety, pharmacokinetic and efficacy results are being presented at the World Conference on Lung Cancer (WCLC) 2025 in Barcelona (Abstract ID-2859).
  • 09 Sep 2025 Results published in the Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top